Meet In CommonNewsRSS feeds

Local

IDEAYA Biosciences Announces Successful US FDA Type C Meeting on Phase 2/3 Registrational Trial Designs to Support Potential Accelerated and Full Approval for IDE849, a Potential Best-in-Class DLL3 TOP1 ADC, in Neuroendocrine Carcinomas

Meet in Common connects news with real conversations. Use ThinkMatch to arrange a Roundtable and meet people to discuss this story.

Roundtables are designed for groups of four, with a shared subject and room for everyone to speak. Come for discussion, with no dating expectation.

Source: Clearwater Tribune

Single-arm extension cohort of approximately 90 refractory GEP-NEC patients to support potential accelerated approval, with ORR by BICR as the primary endpointRandomized Phase 3 trial in multiple refractory NEC subtypes, including GEP-NEC and LC-NEC, is planned to support full approval,…

This excerpt comes from the named source. Read the original for the full reporting.

Read the original at Clearwater Tribune

Featured places to meet in Palo Alto, CA

Explore these places and arrange a conversation through ThinkMatch.

City guide for Palo Alto, CA

Related coverage

Community Poll

Studies used in public decisions should include people from varied backgrounds.

Share your view, then see how readers voted. No sign-in required. This poll is shared across stories.

Do you agree or disagree?

Choose one answer

Common Quandary

A Common Quandary to discuss

Another conversation to explore, separate from this news story.

The buffet is unlimited while you are inside. Can one sandwich leave in your pocket?

An expensive hotel brunch advertises unlimited food but forbids takeout. You are full, yet quietly assembling a sandwich for later would cost the hotel almost nothing. Several trays will likely be discarded after service.

Does preventing waste justify ignoring the boundary of a bargain?

Explore this quandary